IRRAS AB (PUBL) INTERIM REPORT JANUARY–SEPTEMBER 2018
Preparation for US launch of IRRAflow® ongoing, CE mark catheter re-certification now expected at YE 2018 Third quarter, July–September 2018 · Net revenue totaled SEK 0.0 million (11.3). · Operating loss (EBIT) amounted to SEK -40.0 million (-7.2). · Loss after tax totaled SEK -41.8 million (-7.3). · Earnings per share before and after dilution amounted to SEK -1.75 (-0.42). Full year to date January–September 2018 · Net revenue totaled SEK 6.0 million (11.3). · Operating loss (EBIT) amounted to SEK -93.2 million (-37.8). · Loss after tax totaled SEK -88.8